NCE Discovery, a specialist medicinal chemistry and drug design service provider, has entered into an agreement with US-based Dara BioSciences to work on the development of new drug target molecules
Dara BioSciences discovers and develops small molecule treatments for metabolic and CNS diseases and, under the terms of the agreement, will have access to NCED's full range of medicinal chemistry expertise, initially to address two specific drug targets.
"This collaboration is another prime example of NCE Discovery's successful operations as a service provider in the US pharmaceutical market," said Chris Sharman, NCED's CEO.
"We welcome the opportunity to work with the team at Dara BioSciences to speed up the discovery and development of important new medicines".
John Didsbury, chief scientific officer at Dara BioSciences, commented: "We are looking forward to working with NCED and believe that the medicinal chemistry capabilities it brings to the collaboration will help tremendously with our development program of potential new therapies".
NCE Discovery provides a range of specialist medicinal chemistry services to help its clients to accelerate their drug discovery programmes, from initial planning through to target identification of clinical drug candidates.
